NCT05854498RecruitingPhase 2
Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer
Phase II Study of Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer
Source: ClinicalTrials.gov · Last updated 15 Sept 2026
Brief summary (registry, in English)
This study is being done to see if combining liposomal irinotecan with TAS102 and bevacizumab confers clinical benefit for patients with treatment refractory metastatic colorectal cancer.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 2 May 2023
- Start date
- 13 Oct 2023
- Primary completion date
- Sept 2028
- Lead sponsor
- University of Wisconsin, Madison
- Diseases
- Colorectal cancer
- NCT number
- NCT05854498
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 50
- From 13 Oct 2023 to the primary completion date, Sept 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Uncontrolled concurrent medical illness that would not allow for the completion of the planned therapy.
- Patients must stop the use of strong inducers/inhibitors of CYP3A4 at least 2 weeks before initiating therapy.
- Patients must not have received prior TAS102.
Other illness
- Patients whose cancers possess BRAF V600 mutations are excluded.
- Patients must not have mismatch repair deficient or microsatellite instability high cancers.
Who the study is looking for
- Patients must be ≥ 18 years of age
- Eastern Cooperative Oncology Group (ECOG) performance must be 0 or 1.
- Patients must have a histologically or cytologically confirmed diagnosis of colorectal adenocarcinoma and be metastatic or unresectable.
- The cancer must be mismatch repair proficient.
- Patients must have had prior treatment with 5-fluorouracil, oxaliplatin, irinotecan containing regimens. If RAS wild-type must have received prior anti-EGFR therapy with either cetuximab or panitumumab. If RAS wild-type and HER2 positive then must have had a prior HER2 targeted therapy.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Wisconsin Carbone Cancer Center Coordinator of this site? Confirm its status | Madison | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.